Updates in Osteoporosis: Where They 'Fall Short'

Moderator(s)

• 

  Maria I. ("Maio") Danila, MD, MSc, MPH

  University of Alabama at Birmingham (UAB), Birmingham VA Medical Center
  Birmingham, Alabama, United States

  Disclosure(s): Boehringer-Ingelheim: Advisor or Review Panel Member (Terminated, October 25, 2024); Pfizer: Grant/Research Support (Terminated, September 30, 2024)
• 

  Nancy Lane, MD, BA

  University of California at Davis, School of Medicine
  Hillsborough, California, United States

  Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)

Session Coordinator(s)

• 

  Lesley Jackson, MD, MPH

  University of Alabama at Birmingham
  Vestavia, AL, United States

  Disclosure information not submitted.
• 

  Nancy Lane, MD, BA

  University of California at Davis, School of Medicine
  Hillsborough, California, United States

  Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)

Session will be directed toward a primarily clinical audience. Part 1 focuses on diagnosis of osteoporosis. The speaker will discuss current imaging modalities and tools for risk stratification including DXA, FRAX, QTC, ultrasound, and opportunistic imaging for diagnosing osteoporosis, as examples. Part 2 focuses on management of osteoporosis, particularly in people with renal insufficiency.

Presentations:

• 8:30 AM – 9:00 AM Central Time

  Identify and Stratify Osteoporosis Risk Using Current Diagnostic Tools
  

  Speaker: Elaine Yu, MD, MMSc – Harvard Medical School
• 9:00 AM – 9:30 AM Central Time

  Apply Updated Clinical Guidelines to Manage Osteoporosis in Special Patient Populations
  

  Speaker: Sharon M. Moe, MD – Indiana University